**Requirements for Programme 8 – Medicines for children with mental and behavioural disorders.**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| # | **International non-proprietary name** | **Form of presentation** | **Estimated Demand, 100 %** | **Estimated Quantity under the Assets Allocated in 2021** |
| 1 | Risperidone | oral solution | 286,710\* | 286,710\* |
| 2 | Risperidone | tablet | 155,220 | 155,220 |
| 3 | Risperidone | tablet | 56,580 | 56,580 |
| 4 | Aripiprazole | tablet | 20,972 | 20,972 |
| 5 | Aripiprazole | tablet | 23,550 | 23,550 |
| 6 | Aripiprazole | tablet | 4,710 | 4,710 |
| 7 | Olanzapine | tablet | 29,596 | 29,596 |
| 8 | Methylphenidate | tablet, immediate-release capsule | 8,820 | 8,820 |
| 9 | Vigabatrin | tablet, capsule, pill | 42,020 | 42,020 |
| 10 | Methylphenidate | tablet, delayed-release capsule | 10,800 | 10,800 |
| 11 | Atomoxetine | capsule | 17,550 | 17,550 |
| 12 | Atomoxetine | capsule | 59,580 | 59,580 |
| 13 | Atomoxetine | capsule | 82,170 | 82,170 |
| 14 | Atomoxetine | capsule | 42,330 | 42,330 |
| 15 | Atomoxetine | capsule | 9,180 | 9,180 |
| 16 | Atomoxetine | capsule | 1,080 | 1,080 |
| 17 | Fluoxetine | tablet. capsule | 10,290 | 10,290 |
| 18 | Valproic acid salts | syrup | 24,900,480\* | 24,900,480\* |
| 19 | Valproic acid salts | tablet | 47,400 | 47,400 |
| 20 | Valproic acid salts | tablet, delayed-release capsule | 71,600 | 71,600 |
| 21 | Valproic acid salts | tablet | 19,650 | 19,650 |
| 22 | Valproic acid salts | tablet, delayed-release capsule | 13,650 | 13,650 |
| 23 | Levetiracetam | oral solution | 40,800\*\* | 40,800\*\* |
| 24 | Levetiracetam | tablet | 18,240 | 18,240 |
| 25 | Levetiracetam | tablet | 19,950 | 19,950 |
| 26 | Lamotrigine | dispersible tablet | 29,850 | 29,850 |
| 27 | Lamotrigine | dispersible tablet | 10,350 | 10,350 |

\* - quantity in milligrams

\*\* - quantity in millilitres\